gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide has been researched along with Chronic Kidney Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charytan, C; Chow, S; Ervin, JE; Girndt, M; Houser, P; Janssen, RS; Lehrner, L; Linfert, D; Manllo-Karim, R; Michelsen, A; Shemin, D; Symonian-Silver, M; Xie, F | 1 |
1 trial(s) available for gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide and Chronic Kidney Diseases
| Article | Year |
|---|---|
Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
Topics: Adult; Aged; Endoglin; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Humans; Male; Renal Insufficiency, Chronic | 2023 |